IMPORTANT NOTICE

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN ANY JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL.

IMPORTANT: You must read the following disclaimer before continuing.   The following disclaimer applies to the attached offer to purchase (the “Offer to Purchase”) and any other materials included on this website (together, the “Offer Materials”). You are therefore required to read this disclaimer page carefully before accessing, reading or making any other use of the Offer to Purchase.  By accessing this website, you agree (in addition to giving the representations below) to be bound by the following terms and conditions, including any modifications to them from time to time, each time you receive any information from Citigroup Global Markets Europe AG, Goldman Sachs & Co. LLC, Mizuho Securities Europe GmbH, MUFG Securities (Europe) N.V. and PNC Capital Markets LLC (the "Dealer Managers") and/or D.F. King (the "Information and Tender Agent") as a result of such access.  Capitalized terms used but not otherwise defined in this disclaimer shall have the meaning given to them in the Offer to Purchase.

THE OFFER TO PURCHASE MAY NOT BE FORWARDED OR DISTRIBUTED TO ANY OTHER PERSON AND MAY NOT BE REPRODUCED IN ANY MANNER WHATSOEVER. THE OFFER TO PURCHASE MAY ONLY BE DISTRIBUTED TO PERSONS TO WHOM IT IS OTHERWISE LAWFUL TO SEND THE OFFER TO PURCHASE.  ANY FORWARDING, DISTRIBUTION OR REPRODUCTION OF THE OFFER TO PURCHASE IN WHOLE OR IN PART IS UNAUTHORIZED.  FAILURE TO COMPLY WITH THIS DIRECTIVE MAY RESULT IN A VIOLATION OF APPLICABLE LAWS.

Confirmation of your representation  : In order to be eligible to view the Offer to Purchase or make an investment decision with respect to the Offer (as defined below), you must be able to participate lawfully in the invitations by Teva Pharmaceutical Industries Limited (the “Company”) to holders of Teva Pharmaceutical Finance Netherlands III B.V.’s 7.125% Senior Notes due 2025 (CUSIP 88167AAN1 / ISIN US88167AAN19 (Registered), CUSIP 88167A AM3 / ISIN US88167AAM36 (144A), CUSIP N8540W AC8 / ISIN USN8540WAC84 (Reg S)), holders of Teva Pharmaceutical Finance Netherlands II B.V.’s 6.000% Senior Notes due 2025 ( Common Code 208396323 / ISIN XS2083963236 (144A), Common Code 208396269 / ISIN XS2083962691 (Reg S)), holders of Teva Pharmaceutical Finance Netherlands II B.V.’s 4.500% Senior Notes due 2025 (CUSIP XS1813724603 (Registered), Common Code 178945947 / ISIN XS1789459473 / (144A), Common Code 178945602 / XS1789456024 (RegS)), holders of Teva Pharmaceutical Finance Netherlands III B.V.’s 2.800% Senior Notes due 2023 (CUSIP 88167A AD3 / US88167AAD37 (Registered)), holders of Teva Pharmaceutical Finance Netherlands III B.V.’s 6.000% Senior Notes due 2024 (CUSIP 88167AAL5/ ISIN US88167AAL52 (Registered), CUSIP 88167A AH4 / ISIN US88167AAH41(144A), CUSIP N8540W AA2 / ISIN USN8540WAA29 (RegS)) and holders of Teva Pharmaceutical Finance Netherlands III B.V.’s 3.150% Senior Notes due 2026 (CUSIP 88167A AE1 / ISIN US88167AAE10 (Registered)) (collectively, the “Notes”) to tender their Notes for purchase by the Company for cash (the "Offer") on the terms and subject to the conditions set out in the Offer to Purchase. The Offer to Purchase may have been sent to you at your request and by accessing the Offer to Purchase you shall be deemed to have represented to the Company, the Dealer Managers and the Information and Tender Agent that:

i) you are a holder or a beneficial owner of the Notes;

ii) you are a person to whom it is lawful to send the Offer to Purchase or to make an invitation pursuant to the Offer, in accordance with applicable laws; and

iii) you consent to delivery of the Offer to Purchase by electronic transmission.

By accessing this website, you will be given access to the Offer Materials in electronic form.  You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission and consequently none of the Company, the Dealer Managers, the Information and Tender Agent or any person who controls, or is a director, officer, employee, agent or affiliate of, any such person accepts any liability or responsibility whatsoever in respect of any difference between the Offer to Purchase distributed to you in electronic format and the hard copy version available to you on request from the Information and Tender Agent.

You are also reminded that the Offer to Purchase has been transmitted to you on the basis that you are a person into whose possession the Offer to Purchase may be lawfully delivered in accordance with the laws of the jurisdiction in which you are located or resident and you may not, nor are you authorized to, deliver the Offer to Purchase to any other person.

If you have recently sold or otherwise transferred your entire holding(s) of the Notes, you should inform the Information and Tender Agent immediately.

SECURITIES MAY NOT BE OFFERED, SOLD OR DELIVERED IN THE UNITED STATES ABSENT REGISTRATION UNDER, OR AN EXEMPTION FROM, THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED.

THE OFFER TO PURCHASE AND THE RELATED DOCUMENTS DO NOT CONSTITUTE AN OFFER TO BUY OR THE SOLICITATION OF AN OFFER TO SELL NOTES IN ANY JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION IS UNLAWFUL.  IN THOSE JURISDICTIONS WHERE THE SECURITIES, BLUE SKY OR OTHER LAWS REQUIRE THE OFFER TO BE MADE BY A LICENSED BROKER OR DEALER, THE OFFER SHALL BE DEEMED TO BE MADE ON BEHALF OF THE COMPANY BY THE DEALER MANAGERS OR ONE OR MORE REGISTERED BROKERS OR DEALERS LICENSED UNDER THE LAWS OF SUCH JURISDICTION.  NEITHER THE DELIVERY OF THE OFFER TO PURCHASE NOR ANY PURCHASE OF NOTES SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY INFERENCE THAT THERE HAS BEEN NO CHANGE IN THE COMPANY’S AFFAIRS SINCE THE DATE OF THE OFFER TO PURCHASE, OR THAT THE INFORMATION INCLUDED OR INCORPORATED BY REFERENCE IN THE OFFER TO PURCHASE IS CORRECT AS OF ANY TIME SUBSEQUENT TO THE DATE OF THE OFFER TO PURCHASE OR ANY INFORMATION INCORPORATED BY REFERENCE THEREIN.

NONE OF THE OFFER MATERIAL HAS BEEN FILED WITH OR REVIEWED BY THE SECURITIES AND EXCHANGE COMMISSION, ANY STATE SECURITIES COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAS ANY SUCH COMMISSION OR AUTHORITY PASSED UPON THE ACCURACY OR ADEQUACY OF THE OFFER TO PURCHASE OR ANY OF THE ACCOMPANYING ANCILLARY DOCUMENTS DELIVERED THEREWITH.  ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL AND MAY BE A CRIMINAL OFFENSE.

THE DISTRIBUTION OF THE OFFER MATERIALS IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW.  PERSONS INTO WHOSE POSSESSION THE OFFER MATERIALS COME ARE REQUIRED BY THE COMPANY AND THE INFORMATION AND TENDER AGENT TO INFORM THEMSELVES ABOUT, AND TO OBSERVE, ANY SUCH RESTRICTIONS.